Enumeral Biomedical Holdings, Inc. – Amendment No. 1 to Letter Agreement (June 14th, 2017)
This Amendment No. 1 to Letter Agreement (the "Amendment"), dated as of June 9, 2017, amends that certain letter agreement (the "Letter Agreement"), dated as of August 4, 2016, by and between Enumeral Biomedical Holdings, Inc. (with its subsidiaries, the "Company") and Arthur H. Tinkelenberg, Ph.D. ("Executive"). Capitalized word used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Letter Agreement.
Enumeral Biomedical Holdings, Inc. – Subscription Agreement (November 10th, 2016)
THIS SUBSCRIPTION AGREEMENT (this "Agreement"), dated as of July 29, 2016, is entered into by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (the "Company"), and the Buyer(s) set forth on the signature page(s) affixed hereto (individually, a "Buyer" or collectively, the "Buyers").
Enumeral Biomedical Holdings, Inc. – August 4, 2016 (August 10th, 2016)
Enumeral Biomedical Holdings, Inc. – Fourth Amendment (May 13th, 2016)
This Fourth Amendment, effective as of the date set forth above the signatures of the parties below (the "Effective Date"), amends the Exclusive Patent License Agreement dated April 15, 2011 by and between the Massachusetts Institute of Technology ("M.I.T."), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, and Enumeral Biomedical Corp., a Delaware Corporation having its principal place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 ("COMPANY"), as amended by the First Amendment effective March 8, 2013, the Second Amendment effective July 16, 2014, and by the Third Amendment effective April 15, 2015 (the "LICENSE AGREEMENT"). Capitalized terms used herein without definition shall have the meaning given such terms in the LICENSE AGREEMENT.